BLTE News and Press, Belite Bio Inc From 07/19/22

LBS-008 (a/k/a Tinlarebant) is the Company’s orally administered tablet for the treatment of Stargardt disease (STGD1) There are currently no approved treatments for STGD1 Approximately 30,000 patients in the U.S. suffer from STGD1 A 2-year Phase 2 trial in adolescent...

Meta ( NASDAQ: META ) represented one of the biggest name stocks seeing a midday move on Friday. Shares of the Facebook parent edged lower as it cut back on its hiring plans in the face of a cautious economic forecast. Meanwhile, PureCycle ( PCT ) also made the list of midda...

Benchmark analyst Bruce Jackson initiated coverage of Belite Bio ( BLTE ) with a Buy rating and $57 price target. The clinical-stage biopharmaceutical company's lead asset is LBS-008, which is designed to slow retinal degeneration in dry Age-Related Macular Degeneration, or d...

Belite Bio Inc (NSC:BLTE) is a company whose shares are active, trading 100.7% higher to $30.10. Belite Bio Inc share prices have moved between a 52-week high of $31.27 and a 52-week low of $8.80 and are now trading 242% above that low price at $30.10 per share. Receive IBN Spotlights ...

Belite Bio Inc (NSC:BLTE) is one of today's biggest movers, up 97.0% to $29.55. In the past 52 weeks, shares of Belite Bio Inc have traded between a low of $8.80 and a high of $30.99 and is now at $29.55, which is 236% above that low price. Receive IBN Spotlights - "Bite Size" Small, M...

Gainers: Evoke Pharma EVOK +52%. Zynerba Pharmaceuticals (ZYNE) +18%. LifeMD (LFMD) +13%. Vivos Therapeutics (VVOS) +12%. ACADIA Pharmaceuticals ACAD +11%. Losers: 180 Life Sciences (ATNF) -31%. Belite Bio (BLTE) -19%. VectivBio VECT -14%...

Gainers: Revlon (REV) +98%. biote (BTMD) +61%. Cepton (CPTN) +40%. Alpha Teknova (TKNO) +23%. New Oriental Education & Technology (EDU) +23%. Owlet (OWLT) +21%. Belite Bio (BLTE) +21%. Kaival Brands Innovations Group (KAVL) +20%. iQIYI (IQ) +17%. NIO (NIO) +16%. Redbox Entertainment (RDBX...

Drug developer Belite Bio (BLTE) shares jumped 13% Monday amid a significant sell-off in the broader market, trading 247% above its initial public offering price. Belite (BLTE) shares opened at $18.80, climbing to a high of $24.75 in early afternoon trading. The stock recently changed hands a...

Gainers: Day One Biopharmaceuticals (DAWN) +111%. Ekso Bionics Holdings (EKSO) +22%. OptiNose (OPTN) +19%. Tivic Health Systems (TIVC) +10%. Belite Bio (BLTE) +7%. Losers: ContraFect (CFRX) -23%. Reviva Pharmaceuticals Holdings (RVPH) -20%. Neptune Wellness Solutions (NEPT) -19%. Sc...

SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical stage biopharmaceutical drug development company targeting currently untreatable eye diseases such as dry AMD and Stargardt disease, and metabol...